PCOS is now PMOS: Why a new name could change women’s healthcare

For decades, millions of women were told they had polycystic ovary syndrome, or PCOS. The name sounded clinical, but it was also misleading. It made the condition seem like a problem of “cysts” and ovaries, when in reality many patients never had ovarian cysts at all. Worse, the name helped trap a complex hormonal and metabolic condition inside a narrow reproductive box.

That is now changing.

In May 2026, a major global expert group announced that PCOS will now be known as PMOS: Polyendocrine Metabolic Ovarian Syndrome. The change was introduced in The Lancet and presented at the European Congress of Endocrinology in Prague, following more than a decade of consultation with clinicians, researchers, patients and advocacy organisations.

The new name may look like a small shift, just one letter changed, but medically and socially, it is a big correction.

Why was PCOS renamed?

The old name, polycystic ovary syndrome, suggested that ovarian cysts were central to the condition. But experts now stress that this was never accurate enough. Many people with PCOS do not have cysts, and ovarian cysts are not required for diagnosis. The World Health Organization states that diagnosis can be made when at least two of three features are present: high androgen levels, irregular or absent periods, and polycystic ovaries on ultrasound, after excluding other causes.

This confusion had real consequences. Patients without visible cysts could be dismissed. Others were told the condition mattered only if they wanted to get pregnant. Many were treated for acne, weight gain, irregular periods or infertility separately, without anyone connecting the dots.

The new name, Polyendocrine Metabolic Ovarian Syndrome, tries to describe the condition more honestly. “Polyendocrine” points to the involvement of multiple hormonal systems. “Metabolic” recognises links with insulin resistance, weight changes, type 2 diabetes and cardiovascular risks. “Ovarian” remains in the name because the ovaries are still part of the condition, but they are no longer treated as the whole story.

A condition affecting more than fertility

PMOS is not simply a period problem. It is not simply a fertility problem. It is not simply about weight either.

It can affect menstrual cycles, ovulation, skin, hair growth, body weight, insulin function, cholesterol, blood pressure and mental health. WHO describes PCOS as a chronic metabolic condition that can continue beyond the reproductive years and is associated with insulin resistance, type 2 diabetes, obesity and emotional health concerns such as anxiety, depression, eating disorders and negative body image.

This is why the name change matters. A woman who walks into a clinic with acne, facial hair, irregular periods, weight gain and exhaustion should not have to wait years before someone considers a wider hormonal-metabolic disorder. The new terminology pushes healthcare systems to stop treating PMOS as a minor gynaecological inconvenience and start recognising it as a long-term health condition.

How big is the problem?

The scale is huge. The Endocrine Society says the condition affects about 1 in 8 women, or more than 170 million women worldwide. WHO estimates that PCOS affects 10–13% of reproductive-aged women, and up to 70% of affected women remain undiagnosed globally.

That means many women are living with symptoms without a clear explanation. Some are told to “lose weight.” Some are prescribed pills without proper counselling. Some are only diagnosed after years of infertility struggles. Others are told their symptoms are cosmetic, emotional or lifestyle-related, when their body is signalling a deeper endocrine and metabolic imbalance.

The renaming was not sudden

Although the announcement feels recent, the process was long. According to reporting by STAT, debate over renaming the condition goes back more than a decade, with disagreement among experts before wider consultation eventually shaped the final name. Around 22,000 people, including patients, clinicians, researchers and advocacy groups, contributed to the process.

The Endocrine Society says more than 50 patient and professional organisations were involved, and the transition to PMOS will be supported by a three-year global education and awareness campaign, with full implementation expected in the 2028 International Guideline update.

So, this is not just a branding exercise. It is an attempt to change medical education, clinical guidelines, public understanding and research priorities.

Will diagnosis or treatment change immediately?

Not immediately.

For now, the name is changing faster than the diagnostic system. The basic diagnostic features remain similar: irregular or absent periods, signs or blood evidence of high androgens, and/or polycystic ovaries, after other conditions are ruled out.

But the framing may change care. A doctor using the PMOS lens is more likely to ask broader questions: Is there insulin resistance? Are cholesterol and blood pressure being monitored? Is the patient struggling with anxiety, depression or body image? Is there a long-term risk of diabetes or cardiovascular disease? Is the patient being treated as a whole person rather than a reproductive system?

That is the real promise of PMOS.

Why patients should care

For patients, the new name offers validation. It tells them: this was never “just cysts.” It was never “just periods.” It was never “just weight.” It was always a multi-system condition that deserved serious attention.

But there is a risk too. A new name can create confusion. Some patients may wonder whether they have a new disease. They do not. PMOS is the new name for the condition previously known as PCOS. The science has not suddenly changed overnight; the language is finally catching up with what researchers and patients have known for years.

The bigger issue: medicine listened late

The renaming of PCOS to PMOS is a landmark moment, but it also exposes a failure. Women have been saying for years that the condition affects far more than their ovaries. They have described fatigue, insulin problems, hair growth, acne, mood changes, shame, fertility fears and repeated dismissal in clinics.

Now, medical language is finally beginning to reflect that reality.

A name will not fix underdiagnosis by itself. It will not guarantee better doctors, affordable testing or compassionate care. But it can shift the starting point. And in medicine, the starting point matters. What a condition is called influences what doctors look for, what researchers study, what patients understand and what health systems fund.

PMOS is not just a new acronym. It is an overdue correction.

The views expressed in this article are solely those of the author and do not necessarily reflect the views of The Opinion Desk.